revaprazan   Click here for help

GtoPdb Ligand ID: 12007

Synonyms: Revanex® | YH-1885 | YH1885
Approved drug
revaprazan is an approved drug (S Korea (2007))
Compound class: Synthetic organic
Comment: Revaprazan (YH-1885) is a K+-competitive acid blocker (P-CAB)/proton pump inhibitor [1-2]. First in human data demonstrating the on-target effect of revaprazan were reported in 2010 [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 41.05
Molecular weight 362.19
XLogP 5.51
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(cc1)Nc1nc(c(c(n1)C)C)N1CCc2c(C1C)cccc2
Isomeric SMILES CC1c2ccccc2CCN1c1nc(nc(c1C)C)Nc1ccc(cc1)F
InChI InChI=1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26)
InChI Key LECZXZOBEZITCL-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Revaprazan is used to reduce gastric acid secretion as a mechanism to treat duodenal ulcer, gastric ulcer and gastritis. It is approved for use in South Korea, but not in the US, EU or UK.